» Articles » PMID: 34676370

Lipid Nanoparticle Formulation of Niclosamide (nano NCM) Effectively Inhibits SARS-CoV-2 Replication

Overview
Journal Precis Nanomed
Date 2021 Oct 22
PMID 34676370
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

As exemplified by the COVID-19 pandemic, highly infective respiratory viruses can spread rapidly in the population because of lack of effective approaches to control viral replication and spread. Niclosamide (NCM) is an old anthelminthic drug (World Health Organization essential medicine list) with pleiotropic pharmacological activities. Several recent publications demonstrated that NCM has broad antiviral activities and potently inhibits viral replication, including replication of SARS-CoV-2, SARS-CoV, and dengue viruses. Unfortunately, NCM is almost completely insoluble in water, which limits its clinical use. We developed a cost-effective lipid nanoparticle formulation of NCM (nano NCM) using only FDA-approved excipient and demonstrated potency against SARS-CoV-2 infection in cells (Vero E6 and ACE2-expressing lung epithelium cells).

Citing Articles

Revisiting Niclosamide Formulation Approaches - a Pathway Toward Drug Repositioning.

Jug M, Laffleur F, Millotti G Drug Des Devel Ther. 2024; 18:4153-4182.

PMID: 39308694 PMC: 11416123. DOI: 10.2147/DDDT.S473178.


Insight into Preventing Global Dengue Spread: Nanoengineered Niclosamide for Viral Infections.

Rejinold N, Jin G, Choy J Nano Lett. 2024; 24(46):14541-14551.

PMID: 39194045 PMC: 11583367. DOI: 10.1021/acs.nanolett.4c02845.


Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power-law based pharmacokinetic modeling.

Kim T, Jung W, Cho S, Kim G, Yun H, Chae J Clin Transl Sci. 2024; 17(5):e13833.

PMID: 38797873 PMC: 11128490. DOI: 10.1111/cts.13833.


Niclosamide - encapsulated lipid nanoparticles for the reversal of pulmonary fibrosis.

Yu Y, Liu H, Yuan L, Pan M, Bei Z, Ye T Mater Today Bio. 2024; 25:100980.

PMID: 38434573 PMC: 10907778. DOI: 10.1016/j.mtbio.2024.100980.


Local Complement Contributes to Pathogenic Activation of Lung Endothelial Cells in SARS-CoV-2 Infection.

Zhang H, Gerasimovskaya E, McCarthy M, May N, Prasad R, Riddle S Am J Respir Cell Mol Biol. 2023; 69(2):210-219.

PMID: 37071849 PMC: 10399142. DOI: 10.1165/rcmb.2022-0373OC.


References
1.
Mazzon M, Ortega-Prieto A, Imrie D, Luft C, Hess L, Czieso S . Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry. Viruses. 2019; 11(2). PMC: 6410080. DOI: 10.3390/v11020176. View

2.
Jung E, Nam S, Oh H, Jun S, Ro H, Kim B . Neutralization of Acidic Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of the Dengue Virus Life Cycle In Vitro. Sci Rep. 2019; 9(1):8682. PMC: 6582152. DOI: 10.1038/s41598-019-45095-1. View

3.
Misra S, Jensen T, Pan D . Enriched inhibition of cancer and stem-like cancer cells via STAT-3 modulating niclocelles. Nanoscale. 2015; 7(16):7127-32. DOI: 10.1039/c5nr00403a. View

4.
Sia S, Yan L, Chin A, Fung K, Choy K, Wong A . Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020; 583(7818):834-838. PMC: 7394720. DOI: 10.1038/s41586-020-2342-5. View

5.
Gassen N, Niemeyer D, Muth D, Corman V, Martinelli S, Gassen A . SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nat Commun. 2019; 10(1):5770. PMC: 6920372. DOI: 10.1038/s41467-019-13659-4. View